Neurology

Research improves projection of multiple sclerosis disease progression.

Laquinimod showed superior results in one trial over another in multiple sclerosis patients.

Methods of trail that examined laquinimod for relapsing-remitting multiple sclerosis scrutinized by researchers.

Improved understanding of disease modifying drugs can help patients with MS achieve better outcomes.

Confidence intervals can improve adherence to disease modifying drugs in the care of multiple sclerosis.

New findings may lead to new therapies for multiple sclerosis.

This Continuing Education activity is supported by educational grants from Sanofi-Aventis US Genzyme and Novartis Pharmaceuticals Corporation.

Ozanimod met all primary and secondary endpoints of the RADIANCE trial in patients with relapsing multiple sclerosis.

Ocrevus (ocrelizumab) effective in patients with relapsing and primary progressive multiple sclerosis.

Ocrelizumab (Ocrevus) may improve treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis.

Nutra Pharma and Omnia Biologics will partner to create pediatric multiple sclerosis treatment derived from cobra venom.

People of color who are underrepresented in multiple sclerosis clinical trials need to be engaged.

The FDA has approved 14 disease-modifying medications for use in relapsing forms of multiple sclerosis.

Biogen will discuss results from various studies examining their expansive portfolio of multiple sclerosis drugs.

Novartis experimental drug BAF312 met its primary endpoints in a phase 3 study.

The heavy reliance on MRI abnormalities and the tendency of multiple sclerosis to resemble other rare diseases leads to misdiagnoses.

Test can identify multiple sclerosis from other neurological conditions.

The lack of rigid fatigue descriptions in multiple sclerosis inhibit treatment advances.

Xbox One Kinect platform shown to be effective helping walking gait issues in patient with multiple sclerosis.

Early treatment for multiple sclerosis found to delay relapse.

Limiting oxidative stress could treat Alzheimer’s and Parkinson’s diseases.

Glunomab may inhibit the progression of motor disorders associated with multiple sclerosis.

Glunomab may inhibit the progression of motor disorders associated with multiple sclerosis.

The relevancy of randomized controlled trials of experimental drugs for multiple sclerosis in standard practice called into question.

A small proportion of patients with autoimmune syndrome have diabetes.